Article

Therapeutic Maintenance of Baricitinib and Tofacitinib in Real Life

Valentine Deprez 1,*, Laure Le Monnier 1, Jean-Marc Sobhy-Danial 1, Franck Grados 1, Isabelle Henry-Desailly 1, Sarah Salomon-Goëb 1, Thibault Rabin 1, Sanja Ristic 1, Mathurin Fumery 2, Patrice Fardellone 1 and Vincent Goëb 1

1 Department of Rheumatology, Amiens University Hospital, 80000 Amiens, France; LeMonnier.Laure@chu-amiens.fr (L.L.M.); SobhyDanial.Jean-Marc@chu-amiens.fr (J.-M.S.-D.); Grados.Franck@chu-amiens.fr (F.G.); DesaillyHenry.Isabelle@chu-amiens.fr (I.H.-D.); Salomon.Sarah@chu-amiens.fr (S.S.-G.); Rabin.Thibault@chu-amiens.fr (T.R.); Ristic.Sanja@chu-amiens.fr (S.R.); fardellone.patrice@chu-amiens.fr (P.F.); goeb.vincent@chu-amiens.fr (V.G.)

2 Department of Gastroenterology, Amiens University Hospital, 80000 Amiens, France; fumery.mathurin@chu-amiens.fr

* Correspondence: deprez.valentine@chu-amiens.fr

Received: 29 August 2020; Accepted: 14 October 2020; Published: 16 October 2020

Abstract: Background: Janus kinase inhibitors (JAKis) represent a new alternative to treat rheumatoid arthritis (RA). The objective of this study was to evaluate the effectiveness, tolerance profile, and maintenance of these treatments (tofacitinib and baricitinib) in real life. Methods: All patients in the rheumatology department of Amiens University Hospital treated by JAKis for RA were included from 1 October 2017 to 20 May 2020. Clinical and biological data were provided retrospectively in this observational and single-center study. We aimed to study the JAKi maintenance rate at 12 months and their clinical and biological safety profiles. Results: Fifty-five patients were included. Drug maintenance at 12 months was 67.6%. Factors associated with poorer maintenance were a higher Charlson comorbidity index (HR 1.311 (1.089–1.579); \( p = 0.0042 \)), a higher age (HR 1.055 (1.015–1.096); \( p = 0.0067 \)), and corticosteroids therapy at initiation (HR 2.722 (1.006–7.365); \( p = 0.0487 \)). The clinical and biological safety profile was generally good. Conclusions: Our study found that a higher Charlson index, age, and corticosteroids appeared to be associated with the earlier discontinuation of treatment. JAKis had a response and tolerance profile in real life at least equivalent to that of biological disease-modifying antirheumatic drugs (bDMARDs).

Keywords: rheumatoid arthritis; JAK inhibitors; baricitinib; tofacitinib; therapeutic maintenance

1. Introduction

Rheumatoid arthritis (RA) is the most common chronic inflammatory rheumatic disease [1]. It can cause structural damages, reduce quality of life, and lead to permanent disability. The therapeutic management of RA is therefore essential in rheumatology research and has undergone profound changes over the past few decades. Biological agents have rapidly multiplied, and a new therapeutic class has recently emerged: Janus kinase inhibitors (JAKis).

Janus kinases (JAKs) are essential enzymes in the signaling pathways of many surface cytokine receptors, including those in the inflammatory physiology. JAKis reduce inflammation by modulating the intracellular activity of JAKs and disrupting the signaling of multiple pro-inflammatory cytokines. In France in 2017, two molecules became available in current practice: baricitinib and tofacitinib; these can be prescribed as second-line therapy after conventional synthetic disease-modifying antirheumatic drug (csDMARD) failure [2–5].
Some information about the efficacy and safety profile of these molecules in current practice are now available, but there is still a lack of data about therapeutic maintenance [6–8]. The European League against Rheumatism (EULAR) recommendations in 2019 also raised some concerns about the safety and effectiveness profile of using JAKis after an interleukin 6 (IL6) failure or after another JAKi failure [4].

The main objective of this study was to study JAKi persistence at 12 months as a reflection of the effectiveness and safety profile in real life. The secondary objectives were to identify the factors associated with discontinuation of JAKi therapy, the potential biological issues, the effectiveness profile, and the collection of adverse effects.

2. Materials and Methods

2.1. Patient Selection

This observational, single-center, and retrospective study included all patients having benefited from the introduction of a JAKi for RA in the Rheumatology department of Amiens University Hospital from 1 October 2017 to 20 May 2020. The choice of treatment was left to the discretion of prescribing physicians according to the recommendations of the French Rheumatology Society [9].

All patients were informed about the study’s objectives and agreed to the anonymous use of the collected data. The study was conducted in accordance with the Declaration of Helsinki. The protocol was approved by the Ethics Committee of Department of Clinical Research and Innovation (DRCI) of the Amiens-Picardie University Hospital, and a conformity declaration to a reference methodology to the National Commission for Computing and Civil Liberties (CNIL) was made (Project identification code: PI2020_843_0024).

Inclusion criteria for the patients were:

- RA according to the 2010 ACR/EULAR criteria [10].
- Age 18 years or older.
- Initiation of JAKi therapy.
- No objection to the use of their data.

Non-inclusion criteria were a refusal to participate and patients under legal protection measures.

2.2. Data Recorded

Data were collected as part of routine clinical practice, and electronic medical records were obtained. For each patient, the following variables were recorded from the medical file:

- Baseline characteristics (age, sex, body mass index, history of pulmonary, digestive and urogenital infections, neoplastic history, Charlson comorbidity index [11], and smoking).
- Disease characteristics (duration of RA, positivity of rheumatoid factor (RF) and anticitrullinated protein antibodies (ACPA), presence of extra-articular manifestation, presence of erosion, prior treatments, and concomitant treatments).
- Clinical data at baseline, 3 months, 6 months, and 12 months (number of nocturnal awakenings, duration of morning rusting, pain Visual Analog Scale (VAS), patient global health VAS, disease activity score in 28 joints using erythrocyte sedimentation rate (DAS-28 ESR), disease activity score in 28 joints using C-reactive protein (DAS-28 CRP), number of swollen joints (NSJ), number of tender joints (NTJ), and secondary effects (infections, neoplasia or cardiovascular events)).
- Biological data at baseline, 3 months, 6 months, and 12 months (complete blood count (CBC), sedimentation rate (ESR), C-reactive protein (CRP), liver function, creatinine, modification of diet in renal disease (MDRD) clearance, and lipid profile including total cholesterol, triglycerides, low density lipoprotein cholesterol (LDLc), and high density lipoprotein cholesterol (HDLc)).
2.3. Statistical Analysis

Quantitative variables are expressed as median and quartiles, and categorical variables are expressed as number and percentage. Missing data were not replaced. Drug maintenance was analyzed by the Kaplan–Meier method. The association between treatment discontinuation and baseline characteristics was assessed using a univariate Cox model and presented in terms of a hazard ratio (HR) with 95% confidence interval (CI). \( p < 0.05 \) was considered statistically significant. All statistical analyses were performed using SAS software version 9.4 (SAS Institute Inc, Cary, NC, USA).

3. Results

3.1. Patient Selection and Characteristics

Among 56 patients who met the inclusion criteria, only 55 were included because one patient refused to participate. Seven patients received 5 mg of tofacitinib twice daily, and 48 patients received 4 or 2 mg of baricitinib daily. We observed that six patients (12.5%) received a daily half-dose of 2 mg due to either an age over 75 years or a moderate renal failure, according to the recommendations. Only two out of six patients were able to benefit from the maximum dose of baricitinib due to a good clinical and biological safety profile. Four patients remained on 2 mg of baricitinib daily because of persistent renal failure but with controlled rheumatism at this posology for two patients. The characteristics at baseline of the 55 patients are shown in Table 1. Due to this small sample of patients receiving tofacitinib and the similarity of their characteristics, this study analyzed both molecules together. We could notice that four patients received baricitinib and then tofacitinib with same effectiveness and safety profile (primary inefficacy of two molecules for one patient, secondary inefficacy for another patient, and digestive adverse effects for a third patient). Only one patient with the treatment failure of baricitinib was still on tofacitinib at the time of data collection, i.e., at one year and two months after its introduction. These four patients were analyzed once in the baricitinib group.

Table 1. Baseline characteristics of the study population.

| Characteristic                                      | Whole Population (\( n = 55 \)) |
|----------------------------------------------------|---------------------------------|
| Female sex, \( n \) (%)                            | 45 (81.8%)                      |
| Age (years), \( \text{med} \{Q1–Q3\} \)            | 58.0 [46.0–67.0]                |
| Body mass index (kg/m\(^2\)), \( \text{med} \{Q1–Q3\} \) | 25.9 [22.9–30.5] *              |
| Disease duration (years), \( \text{med} \{Q1–Q3\} \) | 11.0 [4.0–18.0]                 |
| Personal medical history                           |                                 |
| Infection, \( n \) (%)                            | 18/49 (36.7%)                   |
| Neoplasia, \( n \) (%)                            | 4 (7.3%)                        |
| Smoking, \( n \) (%)                              | 12/49 (24.5%)                   |
| Charlson comorbidity index, \( \text{med} \{Q1–Q3\} \) | 2.0 [0.0–3.0]                   |
| DAS-28 ESR, \( \text{med} \{Q1–Q3\} \)            | 4.2 [3.5–4.9]                   |
| DAS-28 CRP, \( \text{med} \{Q1–Q3\} \)            | 4.2 [3.3–4.8]                   |
| Extra-articular manifestations, \( n \) (%)        | 8/53 (15.1%)                    |
| Treatment                                          |                                 |
| Methotrexate at initiation, \( n \) (%)            | 30 (54.5%)                      |
| Methotrexate dose (mg/week), \( \text{med} \{\text{min–max}\} \) | 20.0 (7.5–25.0)                |
| Corticosteroids at initiation, \( n \) (%)         | 23 (41.8%)                      |
| Corticosteroids dose (mg/day), \( \text{med} \{\text{min–max}\} \) | 7 (2–20)                        |
| RF positive, \( n \) (%)                          | 44 (80.0%)                      |
| ACPA positive, \( n \) (%)                        | 43 (78.2%)                      |
| Erosion presence, \( n \) (%)                     | 34 (61.8%)                      |

\( \text{N: number; med: median value; Q1: first quartile; Q3: third quartile; RF: rheumatoid factor; ACPA: anticitrullinated protein antibodies; DAS-28 ESR: disease activity score in 28 joints using erythrocyte sedimentation rate; DAS-28 CRP: disease activity score in 28 joints using C-reactive protein; * missing data for 21 patients.} \)
3.2. JAKi Maintenance

The following-up median was 11.2 months (3.3–12.0). As shown in Table 2 and Figure 1, the rate of drug maintenance at 12 months was 67.6% (52.47–78.85).

| Table 2. Therapeutic maintenance of Janus kinase inhibitors. |
|-------------------------------------------------------------|
|                | Total  | Baricitinib | Tofacitinib |
| Stop/Censure   | 16/39  | 13/35       | 3/4         |
|                | Kaplan–Meier (CI 95%) |       |
| 3 months       | 86.89% [74.43–93.53] | 84.9% [70.88–92.51] | 100.0% [100.0–100.0] |
| 6 months       | 74.45% [59.99–84.33] | 75.1% [59.41–85.43] | 71.43% [25.82–91.98] |
| 9 months       | 69.93% [55.0–80.74] | 69.74% [53.4–81.29] | 71.43% [25.82–91.98] |
| 12 months      | 67.6% [52.47–78.85] | 69.74% [53.4–81.29] | 53.57% [13.2–82.5] |

Figure 1. Janus kinase inhibitor maintenance in time.

3.3. Factors Associated with Discontinuation of JAKis and Adverse Effects

Our univariate analysis revealed three factors statistically associated with JAKi discontinuation: the Charlson comorbidity index (HR 1.358 (1.126–1.638); \( p = 0.0014 \)), age (HR 1.055 (1.015–1.096); \( p = 0.0067 \)), and corticosteroids at initiation (HR 2.722 (1.006–7.365); \( p = 0.0487 \)) (Table 3). No other demographic, clinical, or paraclinical characteristics were found to be associated with drug discontinuation.
Table 3. Factors associated with therapy discontinuation.

| Parameters                                      | HR    | Lower 95% CI | Upper 95% CI | p-Value |
|------------------------------------------------|-------|--------------|--------------|---------|
| Age (for 1 year)                               | 1.055 | 1.015        | 1.096        | 0.0067  |
| Female vs. male sex                            | 1.851 | 0.420        | 8.164        | 0.4159  |
| Disease duration (for 1 year)                  | 1.021 | 0.964        | 1.083        | 0.4763  |
| Personal medical history                        |       |              |              |         |
| Infections                                     | 1.264 | 0.438        | 3.645        | 0.6647  |
| Neoplasia                                      | 0.806 | 0.106        | 6.108        | 0.8349  |
| Smoking                                        | 0.390 | 0.089        | 1.717        | 0.2132  |
| Charlson comorbidity index (for 1 point)       | 1.358 | 1.126        | 1.638        | 0.0014  |
| DAS28-ESR at initiation (for 1 point)          | 1.324 | 0.882        | 1.987        | 0.1753  |
| DAS28-CRP at initiation (for 1 point)          | 1.091 | 0.709        | 1.680        | 0.6925  |
| Prior treatment                                |       |              |              |         |
| No prior biological treatment versus none      | 0.705 | 0.160        | 3.102        | 0.6438  |
| 1 tumor necrosis factor inhibitor versus none  | 0.573 | 0.143        | 2.296        | 0.4316  |
| 2 or more tumor necrosis factor inhibitors     | 1.151 | 0.346        | 3.830        | 0.8190  |
| Interleukin 6 inhibitor                        | 1.167 | 0.434        | 3.137        | 0.7598  |
| Rituximab                                      | 1.498 | 0.520        | 4.315        | 0.4541  |
| Abatacept                                      | 0.955 | 0.358        | 2.551        | 0.9273  |
| Corticosteroids at initiation                  | 2.722 | 1.006        | 7.365        | 0.0045  |
| Methotrexate at initiation                     | 0.547 | 0.203        | 1.474        | 0.2330  |
| RF and/or ACPA positive                        | 1.318 | 0.299        | 5.809        | 0.7151  |
| Erosion presence                              | 1.116 | 0.405        | 3.072        | 0.8317  |

RF: rheumatoid factor; ACPA: anticitrullinated protein antibodies; DAS-28 ESR: disease activity score in 28 joints using erythrocyte sedimentation rate; DAS-28 CRP: disease activity score in 28 joints using C-reactive protein.

No significant statistical link was found between therapeutic maintenance and prior treatment by IL6 inhibitors ($p = 0.7598$) either with treatment by methotrexate at initiation ($p = 0.2330$) or the absence of prior biological disease-modifying antirheumatic drugs (bDMARDs) ($p = 0.6438$).

The reasons for JAKi discontinuation within 12 months were: primary ineffectiveness in seven patients (43.8%), digestive intolerance in six (37.5%), infectious adverse effects in three (18.8%), secondary inefficacy in one (6.3%), cardiovascular events in one (6.3%), and biological abnormalities in one (6.3%).

The cardiovascular events listed in our study during the 12 months follow-up were: unbalanced arterial hypertension and a myocardial infarction.

The infectious adverse effects listed in our study were: exacerbations of chronic obstructive pulmonary disease, pneumonia, recurrent upper airway infections, recurrent urinary tract infections, and recurrent herpes labialis. No herpetic zoster was recorded.

The laboratory abnormality that led to the discontinuation of treatment was the worsening of chronic renal failure (change from stage 3 to stage 4 of chronic kidney disease).

No patient presented with neoplasia during follow-up.

3.4. Biological Data

The safety of JAKis was evaluated using biological data and the difference between the initiation of treatment and three and six months (Table 4). This study showed a slight decrease in hemoglobin (mean of $-0.5$ g/dL at six months), but we observed that the anemia present at the initiation of treatment in five patients (9.1%) was corrected for all at six months. We also found an elevation of platelets (mean of $41,032$ $/\text{mm}^3$ at six months) and a diminution of polynuclear neutrophils (mean of $-383.4$ $/\text{mm}^3$ at six months) but no difference in liver function, renal function, or lipid profile.

3.5. Effectiveness Profile

The proportion of moderate and good responders, according to the EULAR response criteria, was on the DAS-28 ESR and CRP, respectively, 44.4% and 48.1% at 3 months, 71% and 68.8% at 6 months, and 78.9% and 76.2% at 12 months (Figures 2 and 3) [12]. The clinical parameter evolution is
summarized in Figure 4. There is a clinical report of improvement in a patient’s rheumatoid nodules in terms of the size and functional discomfort in the upper limbs. Regarding corticosteroid withdrawal, 23 patients (41.8% of the population) had corticosteroid therapy associated with JAKis at baseline, 20 patients were analyzed at six months, and eight of them (40%) were weaned off corticosteroids. However, the 12 patients still with corticosteroids had a decreased dosage for eight of them, with an average of 4.8 mg (median of 5 mg with a range of 1–10 mg) against a baseline mean of 8.3 mg (median of 7 mg with a range of 2–20 mg). No difference in methotrexate posology was observed in this study after JAKi initiation.

| Table 4. Biological evolution between baseline, 3 months, and 6 months. |
|---------------------------------------------------------------|
| **Hemoglobin (g/dL), med [Q1–Q3]** | Difference between Baseline and 3 Months | Difference between Baseline and 6 Months |
| ——— | ——— | ——— |
| 56,000 [6000–82,000] | **−0.4 [−1.0–0.1]** | **−0.8 [−1.1–0.1]** |
| 300.0 [−1800–500] | **−300.0 [−1229.5–516.5]** | **−105.0 [−1410–420]** |
| 40.5 [−91–145] | **−24.0 [−91–1–1.0]** | **−24.0 [−1040–655]** |
| 41.0 [−400–792] | **−11.0 [−5.9–0.0]** | **−18.0 [−501–430]** |
| 1.0 [−3.0–7.0] | **−2.0 [−10.0–5.0]** | **−2.0 [−10.0–5.0]** |
| 1.0 [−31.0–24.0] | **−2.0 [−10.0–5.0]** | **−2.0 [−10.0–5.0]** |
| 2.6 [−2.5–7.0] | **−2.0 [−10.0–5.0]** | **−2.0 [−10.0–5.0]** |
| 0.0 [−0.2–0.2] | **−0.0 [−0.4–0.4]** | **−0.0 [−0.4–0.4]** |
| 0.0 [−0.6–0.2] | **−0.0 [−0.6–0.2]** | **−0.0 [−0.6–0.2]** |
| 0.0 [−0.2–0.2] | **−0.0 [−0.2–0.2]** | **−0.0 [−0.2–0.2]** |
| 0.0 [−0.4–0.4] | **−0.0 [−0.4–0.4]** | **−0.0 [−0.4–0.4]** |

*med: median value; Q1: first quartile; Q3: third quartile; ESR: erythrocyte sedimentation rate; CRP: C-reactive protein; LDL: low-density lipoprotein; HDL: high-density lipoprotein; * missing data for 7 patients; ** missing data for 10 patients; † missing data for 25 patients.

Figure 2. European League against Rheumatism (EULAR) response variation on DAS-28 ESR.
Figure 2. European League against Rheumatism (EULAR) response variation on DAS-28 ESR.

Figure 3. EULAR response variation on DAS-28 CRP.

Figure 4. Clinical parameter variation. VAS: Visual Analog Scale.

4. Discussion

Our study evaluated JAKi maintenance in 55 patients with RA in routine practice in the Rheumatology department of Amiens University Hospital. We found 74.45% and 67.6% of patients continuing treatment at 6 and 12 months, respectively. The factors found to be significantly associated with drug discontinuation in univariate analysis at 12 months was a lower Charlson comorbidity index at initiation (HR 1.358 (1.126–1.638); \( p = 0.0014 \)), age (HR 1.055 (1.015–1.096); \( p = 0.0067 \)), and corticosteroids at initiation (HR 2.722 (1.006–7.365); \( p = 0.0487 \)). No atypia was found in adverse events recorded, but the presence of a myocardial infarction in this small sample needs to be highlighted.

Drug maintenance at 12 months in our patients was slightly lower compared to published studies, except for a study published in May 2020 reporting a drug maintenance at 12 months of abatacept of 68% [13]. A study published in 2006 about methotrexate, a first-line treatment for RA, found a therapeutic maintenance of 76%. Another study about tocilizumab in 2017 showed a
4. Discussion

Our study evaluated JAKi maintenance in 55 patients with RA in routine practice in the Rheumatology department of Amiens University Hospital. We found 74.45% and 67.6% of patients continuing treatment at 6 and 12 months, respectively. The factors found to be significantly associated with drug discontinuation in univariate analysis at 12 months was a lower Charlson comorbidity index at initiation (HR 1.358 (1.126–1.638); \( p = 0.0014 \)), age (HR 1.055 (1.015–1.096); \( p = 0.0067 \)), and corticosteroids at initiation (HR 2.722 (1.006–7.365); \( p = 0.0487 \)). No atypia was found in adverse events recorded, but the presence of a myocardial infarction in this small sample needs to be highlighted.

Drug maintenance at 12 months in our patients was slightly lower compared to published studies, except for a study published in May 2020 reporting a drug maintenance at 12 months of abatacept of 68% [13]. A study published in 2006 about methotrexate, a first-line treatment for RA, found a therapeutic maintenance of 76%. Another study about tocilizumab in 2017 showed a therapeutic maintenance of 82.9%, and another study about infliximab in 2008 showed a therapeutic maintenance of 78% [14–16]. We can also quote a study of 2019 that compared therapeutic maintenance for tocilizumab at 12 months between patients treated by intravenous tocilizumab (80%) and patients who switched for subcutaneous tocilizumab (77.7%) [17].

Our population was similar concerning baseline characteristics in comparison with patients in the RA-BEAM study about baricitinib, but our population was older with a longer duration of RA compared to the ORAL-STRATEGY study about tofacitinib [18,19]. Patients in our study had a generally lower active RA at the initiation of JAKis [18–21]. We can explain this difference by the real-life type of this study in which no severe activity of RA could be tolerated.

We included a small number of patients treated by tofacitinib, but our study design had no influence on the choice of rheumatologist. It seems fairly intuitive to say that taking baricitinib once a day is more attractive than taking tofacitinib twice a day for patients, and baricitinib was available in France several months before tofacitinib. Additionally, a European re-evaluation of tofacitinib was carried out in May 2019 following the interim analyses of clinical study A3921133 that demonstrated an increased risk of severe venous thromboembolism compared to tumor necrosis factor inhibitors at a dosage of 10 mg twice daily [22]. This posology is indicated in the gastroenterological setting for treatment of ulcerative colitis but not of RA. However, there may be a greater concern about the use of this molecule compared to baricitinib that may explain this difference in our study.

Regarding the biological follow-up between initiation and three and six months, we did not find any major difference in the hemoglobin level (median differences of \(-0.4\) and \(-0.8 \) g/dL, respectively). However, we noticed that the anemia observed at baseline in 9.1% of patients was corrected at six months for all. Conversely, anemia appeared in 9.4% of patients at six months. Though the initial anemia etiology was not investigated, we can speculate that its disappearance was due to the correction of the biological inflammatory syndrome but also by the direct action of the JAKis, which can influence the process of hematopoiesis [23–25]. Erythropoietin, as well as growth factors of the white line, acts to obtain physiological effects through the JAK system and, in particular, JAK2. The contradiction between correction of anemia and creation of anemia in this study is therefore explained by the fact that we studied two molecules with slightly different modes of action, baricitinib being a more significant inhibitor of JAK2 than tofacitinib. However, finding a correction of anemia at six months for all patients in our population has a clinical interest because anemia is one of the factors of chronic asthenia expressed by a majority of patients regardless of disease control [26,27].

Regarding the adverse events listed in this study, we identified a myocardial infarction and an antral ulcer. Regarding the myocardial infarction, this was a patient with other cardiovascular risk factors, and all studies have been reassuring about the cardiovascular risk of JAKis. This isolated case does not challenge the available large-scale data [7,8]. Likewise, there was a case of antral ulcers in a patient with concomitant use of non-steroidal anti-inflammatory drugs. This type of adverse event is known and described in the literature under JAKis [28]. The main hypothesis regarding the physiology of digestive perforations is that the inhibition of the JAK–STAT system is partly responsible
for the inhibition of IL6 signaling, and digestive perforations are a known and frequent risk with IL6 inhibitors.

Our study found a higher Charlson comorbidity index as a statistically significant factor associated with lower therapeutic maintenance (HR 1.358 (1.126–1.638); \( p = 0.0014 \)). Age, that is part of the Charlson index, and treatment by corticosteroids at baseline were also factors that were statistically associated with lower therapeutic maintenance in our univariate analysis. We could therefore suggest that, according to our study, a higher patient’s Charlson index at the start of treatment is associated with a greater probability of stopping treatment. In other words, the introduction of JAKis in patients with numerous co-morbidities should be discussed. This original sighting has never been described, to our knowledge, in JAKi treatments. Likewise, another Japanese study from 2014 showed a poorer response to biological DMARDs with a higher Charlson index in terms of DAS-28 evolution and quality of life [29]. Conversely, a German study from 2014 found no association between the Charlson index and therapeutic maintenance with adalimumab, etanercept, and infliximab [30]. Our study did not find any statistical difference of therapeutic maintenance for patients with a history of IL6 inhibitor therapy, for patients treated by JAKis with methotrexate, or for patients without prior bDMARDs.

Our study had several limitations. The retrospective characteristic induced a large variation in the duration of treatment, and many patients were censured. The small size of our single-center cohort did not allow us to perform multivariate analysis. Therefore, the association between characteristics at baseline and therapy discontinuation must be interpreted with caution and should be confirmed in multicenter studies of larger scales and longer follow-ups.

5. Conclusions

In view of our study, JAKis had a response and tolerance profile in real life at least equivalent to that of biological disease-modifying antirheumatic drugs. To optimize their prescription, it is suggested to take the patient’s age, his Charlson comorbidity index, and any received corticosteroids therapy into account.

Our study did not find any difference in therapeutic maintenance whether JAKis were administered first-line after the failure of methotrexate, after a history of IL6 inhibitor treatment, or in combination with methotrexate, but these data must be confirmed by other teams on a larger scale.

Author Contributions: Conceptualization, V.G. and V.D.; methodology, V.G. and V.D.; validation and inclusion, all authors; formal analysis, S.R. and V.D.; writing—original draft preparation, V.D.; writing—review and editing, all authors. All authors have read and agreed to the published version of the manuscript.

Funding: This research received no external funding.

Conflicts of Interest: Vincent Goëb has received consulting fees from Abbvie, Lilly, Novartis, Pfizer and Sanofi. Patrice Fardellone has received consulting fees from AMGEN and UCB. Mathurin Fumery has received consultant fees for Abbvie, Ferring, MSD, Tillots, Janssen, Takeda, Celgene, Gilead, Biogen, Pfizer and Boehringer. Laure Le Monnier has received consulting fees from Novartis. Sarah Salomon-Goëb has received consulting fees from Pfizer. Franck Grados has received grants from Lilly for his participation at French Society of Rheumatology congress. Sanja Ristic has received consulting fees from Novartis. Valentine Deprez, Jean-Marc Sobhy-Danial, Isabelle Henry-Desailly and Thibault Rabin, declare that they have no conflict of interest.

References
1. Smolen, J.S.; Aletaha, D.; McInnes, I.B. Rheumatoid arthritis. Lancet 2016, 388, 2023–2038. [CrossRef]
2. Malemud, C.J. The role of the JAK/STAT signal pathway in rheumatoid arthritis. Ther. Adv. Musculoskelet Dis. 2018, 10, 117–127. [CrossRef]
3. Dowty, M.E.; Lin, T.H.; Jesson, M.I.; Hegen, M.; Martin, D.A.; Katkade, V.; Menon, S.; Telliez, J. Janus kinase inhibitors for the treatment of rheumatoid arthritis demonstrate similar profiles of in vitro cytokine receptor inhibition. Pharmacol. Res. Perspect. 2019, 7. [CrossRef] [PubMed]
4. Smolen, J.S.; Landewé, R.B.M.; Bijlsma, J.W.J.; Burmester, G.R.; Dougados, M.; Kerschbaumer, A.; McInnes, I.B.; Sepriano, A.; van Vollenhoven, R.F.; de Wit, M.; et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update. *Ann. Rheum. Dis.* 2020. [CrossRef] [PubMed]

5. Walker, J.G.; Ahern, M.J.; Coleman, M.; Weedon, H.; Papangelis, V.; Beroukas, D.; Roberts-Thomson, P.J.; Smith, M.D. Changes in synovial tissue Jak-STAT expression in rheumatoid arthritis in response to successful DMARD treatment. *Ann. Rheum. Dis.* 2006, 65, 1558–1564. [CrossRef] [PubMed]

6. Verden, A.; Dimbil, M.; Kyle, R.; Overstreet, B.; Hoffman, K.B. Analysis of Spontaneous Postmarket Case Reports Submitted to the FDA Regarding Thromboembolic Adverse Events and JAK Inhibitors. *Drug Saf.* 2018, 41, 357–361. [CrossRef]

7. Taylor, P.C.; Weinblatt, M.E.; Burmester, G.R.; Rooney, T.P.; Witt, S.; Walls, C.D.; Issa, M.; Salinas, C.A.; Saifan, C.; Zhang, X.; et al. Cardiovascular safety during Treatment with Baricitinib in Rheumatoid Arthritis. *Arthritis Rheumatol.* 2019, 71, 1042–1055. [CrossRef]

8. Cohen, S.B.; Tanaka, Y.; Mariette, X.; Curtis, J.R.; Lee, E.B.; Nash, P.; Winthrop, K.L.; Charles-Schoeman, C.; Thirunavukkarasu, K.; DeMasi, R.; et al. Long-term safety of tofacitinib for the treatment of rheumatoid arthritis up to 8.5 years: Integrated analysis of data from the global clinical trials. *Ann. Rheum. Dis.* 2017, 76, 1253–1262. [CrossRef]

9. Daien, C.; Hua, C.; Gaujoux-Viala, C.; Cantagrel, A.; Dubremetz, M.; Dougados, M.; Fautrel, B.; Mariette, X.; Nayral, N.; Richez, C.; et al. Update of French society for rheumatology recommendations for managing rheumatoid arthritis. *Jt. Bone Spine* 2019, 86, 135–150. [CrossRef]

10. Prevoo, M.L.; van’t Hof, M.A.; Kuper, H.H.; van Leeuwen, M.A.; van de Putte, L.B.; van Riel, P.L. Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. *Arthritis Rheum.* 1995, 38, 44–48. [CrossRef] [PubMed]

11. Charlson, M.E.; Pompei, P.; Ales, K.L.; MacKenzie, C.R. A new method of classifying prognostic comorbidity in longitudinal studies: Development and validation. *J. Chronic. Dis.* 1987, 40, 373–383. [CrossRef]

12. Prevo, M.L.; van’t Hof, M.A.; Kuper, H.H.; van Leeuwen, M.A.; van de Putte, L.B.; van Riel, P.L. Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. *Arthritis Rheum.* 2010, 69, 1580–1588. [CrossRef] [PubMed]

13. Salmon, J.-H.; Letarouilly, J.-G.; Goeb, V.; Kanagaratnam, L.; Coquerelle, P.; Guyot, M.-H.; Houvenagel, E.; Lecuyer, N.; Marguerie, L.; Morel, G.; et al. Actual Persistence of Abatacept in Rheumatoid Arthritis: Results of the French-Ric Network. *J. Clin. Med.* 2020, 9, 1528. [CrossRef] [PubMed]

14. Tahiri, L.; Allali, F.; Jroundi, I.; Abouqal, R.; Hajjaj-Hassouni, N. Therapeutic maintenance level of methotrexate in rheumatoid arthritis. *Sante* 2006, 16, 167–172. [CrossRef] [PubMed]

15. Chopin, C.; Pauvele, L.; Jaulerry, S.; Brochet, P.; Eschard, J.-P.; Salmon, J.-H. Effectiveness, therapeutic maintenance and reasons for stopping tocolizumab (TCZ): A retrospective and monocentric study in 88 patients followed for rheumatoid arthritis (RA) at the Reims university hospital. *Therapie* 2018, 73, 231–236. [CrossRef]

16. Figueiredo, I.T.; Morel, J.; Sany, J.; Combe, B. Maintenance and tolerability of infliximab in a cohort of 152 patients with rheumatoid arthritis. *Clin. Exp. Rheumatol.* 2008, 26, 18–23. [PubMed]

17. Darloy, J.; Segaud, N.; Salmon, J.-H.; Eschard, J.-P.; Goeb, V.; Deprez, X.; Guyot, M.-H.; Houvenagel, E.; Lecuyer, N.; Marguerie, L.; et al. Tocilizumab Effectiveness after Switching from Intravenous to Subcutaneous Route in Patients with Rheumatoid Arthritis: The RoSwitch Study. *Rheumatol. Ther.* 2019, 6, 61–75. [CrossRef] [PubMed]

18. Taylor, P.C.; Keystone, E.C.; van der Heijde, D.; Weinblatt, M.E.; Del Carmen Morales, L.; Reyes Gonzaga, J.; Yakushin, S.; Ishii, T.; Emoto, K.; Beattie, S.; et al. Baricitinib versus Placebo or Adalimumab in Rheumatoid Arthritis. *N. Engl. J. Med.* 2017, 376, 652–662. [CrossRef]

19. Fleischmann, R.; Mysler, E.; Hall, S.; Kivitz, A.J.; Moots, R.J.; Luo, Z.; DeMasi, R.; Soma, K.; Zhang, R.; Takiya, L.; et al. Efficacy and safety of tofacitinib monotherapy, tofacitinib with methotrexate, and adalimumab with methotrexate in patients with rheumatoid arthritis (ORAL Strategy): A phase 3b/4, double-blind, head-to-head, randomised controlled trial. *Lancet* 2017, 390, 457–468. [CrossRef]
20. Genovese, M.C.; Kremer, J.; Zamani, O.; Ludivico, C.; Krogulec, M.; Xie, L.; Beattie, S.D.; Koch, A.E.; Cardillo, T.E.; Rooney, T.P.; et al. Baricitinib in Patients with Refractory Rheumatoid Arthritis. *N. Engl. J. Med.* 2016, 374, 1243–1252. [CrossRef]

21. Keystone, E.C.; Taylor, P.C.; Drescher, E.; Schlichting, D.E.; Beattie, S.D.; Berclaz, P.-Y.; Lee, C.H.; Fidelius-Gort, R.K.; Luchi, M.E.; Rooney, T.P.; et al. Safety and efficacy of baricitinib at 24 weeks in patients with rheumatoid arthritis who have had an inadequate response to methotrexate. *Ann. Rheum. Dis.* 2015, 74, 333–340. [CrossRef] [PubMed]

22. XELJANZ (tofacitinib): Restriction d’Utilisation en cas de Risque élevé d’Embolie Pulmonaire. Available online: https://www.vidal.fr/actualites/23360/xeljanz_tofacitinib_restriction_d_utilisation_en_cas_de_risque_eleve_d_embolie_pulmonaire/ (accessed on 5 August 2020).

23. Paul, S.K.; Montvida, O.; Best, J.H.; Gale, S.; Pethoe-Schramm, A.; Sarsour, K. Effectiveness of biologic and non-biologic antirheumatic drugs on anaemia markers in 153,788 patients with rheumatoid arthritis: New evidence from real-world data. *Semin. Arthritis Rheum.* 2018, 47, 478–484. [CrossRef] [PubMed]

24. Choy, E.H. Clinical significance of Janus Kinase inhibitor selectivity. *Rheumatology* 2019, 58, 953–962. [CrossRef] [PubMed]

25. Smolen, J.S.; Genovese, M.C.; Takeuchi, T.; Hyslop, D.L.; Macias, W.L.; Rooney, T.; Chen, L.; Dickson, C.L.; Riddle Camp, J.; Cardillo, T.E.; et al. Safety Profile of Baricitinib in Patients with Active Rheumatoid Arthritis with over 2 Years Median Time in Treatment. *J. Rheumatol.* 2019, 46, 7–18. [CrossRef]

26. Taylor, P.C.; Moore, A.; Vasilescu, R.; Alvir, J.; Tarallo, M. A structured literature review of the burden of illness and unmet needs in patients with rheumatoid arthritis: A current perspective. *Rheumatol. Int.* 2016, 36, 685–695. [CrossRef]

27. Hewlett, S.; Cockshott, Z.; Byron, M.; Kitchen, K.; Tipler, S.; Pope, D.; Hehir, M. Patients’ perceptions of fatigue in rheumatoid arthritis: Overwhelming, uncontrollable, ignored. *Arthritis Rheum.* 2005, 53, 697–702. [CrossRef]

28. Xie, F.; Yun, H.; Bernatsky, S.; Curtis, J.R. Brief Report: Risk of Gastrointestinal Perforation among Rheumatoid Arthritis Patients Receiving Tofacitinib, Tocilizumab, or Other Biologic Treatments. *Arthritis Rheumatol.* 2016, 68, 2612–2617. [CrossRef]

29. Nakajima, A.; Inoue, E.; Shimizu, Y.; Kobayashi, A.; Shidara, K.; Sugimoto, N.; Seto, Y.; Tanaka, E.; Taniguchi, A.; Momohara, S.; et al. Presence of comorbidity affects both treatment strategies and outcomes in disease activity, physical function, and quality of life in patients with rheumatoid arthritis. *Clin. Rheumatol.* 2015, 34, 441–449. [CrossRef] [PubMed]

30. Neubauer, S.; Cifaldi, M.; Mittendorf, T.; Ganguli, A.; Wolff, M.; Zeidler, J. Biologic TNF inhibiting agents for treatment of rheumatoid arthritis: Persistence and dosing patterns in Germany. *Health Econ. Rev.* 2014, 4, 32. [CrossRef] [PubMed]

**Publisher's Note:** MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.

© 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).